|
Q: Would you select an intermediate- or long-acting insulin for PD as her basal insulin?
A: Either a long- or intermediate-acting insulin could be used to begin therapy in this patient. Insulin glargine has a prolonged duration of action and lack of peak effect that allows for once-daily dosing. Another common first choice is NPH insulin, which is an intermediate-acting insulin. NPH insulin has a proven long-term safety record, is less costly, and can be used with a pen device, which is preferred by some patients. In contrast, insulin glargine must be used with a syringe and vial and is more expensive. Insulin glargine cannot be mixed with other insulin preparations.
| 
